RFA2抗体—艾普蒂

+ +

•  

   

     Western blot analysis using RFA2 mouse mAb against Hela (1), MCF-7 (2), T47D (3), Ramos (4), HEK293 (5), HepG2 (6) and A431 (7) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using RFA2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver tissues using RFA2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using RFA2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using RFA2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using RFA2 mouse mAb with DAB staining.    

  
  

The Replication Protein A2 (RFA2/RPA2) antibody is a crucial tool for studying the Replication Protein A (RPA) complex, a conserved eukaryotic single-stranded DNA (ssDNA)-binding protein essential for DNA replication, repair, and recombination. The RPA heterotrimer comprises three subunits: RPA1 (70 kDa), RPA2 (32 kDa), and RPA3 (14 kDa). RPA2 plays a central role in stabilizing the RPA complex and regulating its DNA-binding activity. During DNA damage response, RPA2 undergoes phosphorylation at specific residues (e.g., Ser4/Ser8) by kinases like ATM/ATR, facilitating checkpoint signaling and recruitment of repair factors. This post-translational modification is critical for homologous recombination repair and replication stress responses.

RFA2 antibodies are widely used to investigate RPA2 expression, localization, and phosphorylation dynamics in contexts such as DNA damage (e.g., ionizing radiation or UV exposure), cell cycle regulation, and replication fork stalling. They are applied in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to assess RPA2’s involvement in genomic stability and cancer biology. Dysregulation of RPA2 has been linked to tumorigenesis and chemoresistance, making it a potential biomarker or therapeutic target. Commercial RFA2 antibodies are typically validated in knockout/knockdown models to ensure specificity. Researchers also utilize phospho-specific RPA2 antibodies to study damage-induced signaling cascades, offering insights into mechanisms underlying genome integrity and anticancer drug development.